Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 8/2016

01-08-2016 | Original Article

Linc-ROR induces epithelial-mesenchymal transition and contributes to drug resistance and invasion of breast cancer cells

Authors: Yao-Min Chen, Yu Liu, Hai-Yan Wei, Ke-Zhen Lv, Peifen Fu

Published in: Tumor Biology | Issue 8/2016

Login to get access

Abstract

We aimed to investigate the role of large intergenic noncoding RNA regulator of reprogramming (linc-ROR) in the chemotherapy resistance of human breast cancer (BC) cells and its mechanism. A total of 142 patients diagnosed with BC in the First Affiliated Hospital, Zhejiang University between January 2012 and January 2014 were enrolled in our study. The BC tissues and the adjacent normal tissues (5 cm away from tumor tissue) of the enrolled patients were selected, and human BC cell lines (MCF10A, SK-BR-3, MCF-7, Bcap-37, MDA-MB-231, and T47D) were also selected. Quantitative real-time polymerase chain reaction (qRT-PCR), Western blot, 3-(4, 5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt (MTS) assay, and Transwell were applied in our study. Expression level of linc-ROR messenger RNA (mRNA) in BC tissues was clearly higher than that in adjacent normal tissues, and significant difference was found between expression level of linc-ROR mRNA and lymph node metastasis (all P < 0.05). Linc-ROR was highly expressed in others BC cell lines compared with that in immortalized mammary epithelial cells (MECs) MCF10A (both P < 0.05), while MDA-MB231 cell presented the higher expression (P < 0.001). Under different concentrations of 5-FU and paclitaxel in MDA-MB231 cell, E-cadherin mRNA and protein expressions increased gradually with the increase of concentrations, and Vimentin and N-cadherin mRNA and protein expressions decreased gradually with the decrease of concentrations (all P < 0.05). Compared with shCtrl group, MDA-MB231 cell in shROR group presented higher sensibility of 5-FU and paclitaxel with increased E-cadherin expression, decreased Vimentin and N-cadherin expression and invasion ability (all P < 0.05). Compared with vector cell, overexpressed linc-ROR cell presented decreased sensibility of 5-FU and paclitaxel with decreased E-cadherin expression, increased Vimentin, N-cadherin expression, and invasion ability (all P < 0.05). Our study demonstrated that linc-ROR is an important marker for multidrug resistance of BC, and its up-regulation is important for chemotherapy tolerance and invasion of BC.
Literature
1.
Ghoussaini M, Fletcher O, Michailidou K, Turnbull C, Schmidt MK, Dicks E, et al. Genome-wide association analysis identifies three new breast cancer susceptibility loci. Nat Genet. 2012;44(3):312–8.CrossRefPubMedPubMedCentral
2.
3.
4.
Fredholm H, Eaker S, Frisell J, Holmberg L, Fredriksson I, Lindman H. Breast cancer in young women: poor survival despite intensive treatment. PLoS One. 2009;4(11), e7695.CrossRefPubMedPubMedCentral
5.
Kaminska M, Ciszewski T, Lopacka-Szatan K, Miotla P, Staroslawska E. Breast cancer risk factors. Prz Menopauzalny. 2015;14(3):196–202.PubMedPubMedCentral
6.
Curigliano G, Spitaleri G, Dettori M, Locatelli M, Scarano E, Goldhirsch A. Vaccine immunotherapy in breast cancer treatment: promising, but still early. Expert Rev Anticancer Ther. 2007;7(9):1225–41.CrossRefPubMed
7.
Zhang W, Feng M, Zheng G, Chen Y, Wang X, Pen B, et al. Chemoresistance to 5-fluorouracil induces epithelial-mesenchymal transition via up-regulation of snail in mcf7 human breast cancer cells. Biochem Biophys Res Commun. 2012;417(2):679–85.CrossRefPubMed
8.
Liang Z, Wu H, Xia J, Li Y, Zhang Y, Huang K, et al. Involvement of mir-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1. Biochem Pharmacol. 2010;79(6):817–24.CrossRefPubMed
9.
Consortium EP, Birney E, Stamatoyannopoulos JA, Dutta A, Guigo R, Gingeras TR, et al. Identification and analysis of functional elements in 1% of the human genome by the encode pilot project. Nature. 2007;447(7146):799–816.CrossRef
10.
Hou P, Zhao Y, Li Z, Yao R, Ma M, Gao Y, et al. Lincrna-ror induces epithelial-to-mesenchymal transition and contributes to breast cancer tumorigenesis and metastasis. Cell Death Dis. 2014;5, e1287.CrossRefPubMedPubMedCentral
11.
Guttman M, Amit I, Garber M, French C, Lin MF, Feldser D, et al. Chromatin signature reveals over a thousand highly conserved large non-coding rnas in mammals. Nature. 2009;458(7235):223–7.CrossRefPubMedPubMedCentral
12.
13.
14.
Calin GA, Liu CG, Ferracin M, Hyslop T, Spizzo R, Sevignani C, et al. Ultraconserved regions encoding ncrnas are altered in human leukemias and carcinomas. Cancer Cell. 2007;12(3):215–29.CrossRefPubMed
15.
16.
Yu W, Gius D, Onyango P, Muldoon-Jacobs K, Karp J, Feinberg AP, et al. Epigenetic silencing of tumour suppressor gene p15 by its antisense rna. Nature. 2008;451(7175):202–6.CrossRefPubMedPubMedCentral
17.
Loewer S, Cabili MN, Guttman M, Loh YH, Thomas K, Park IH, et al. Large intergenic non-coding RNA-RoR modulates reprogramming of human induced pluripotent stem cells. Nat Genet. 2010;42(12):1113–7.CrossRefPubMedPubMedCentral
18.
19.
Wang Y, Xu Z, Jiang J, Xu C, Kang J, Xiao L, et al. Endogenous mirna sponge lincrna-ror regulates oct4, nanog, and sox2 in human embryonic stem cell self-renewal. Dev Cell. 2013;25(1):69–80.CrossRefPubMed
20.
M PN. World medical association publishes the revised Declaration of Helsinki. Natl Med J India. 2014;27(1):56.
21.
Penault-Llorca F. Comments on the new American Joint Committee on Cancer TNM staging for breast cancer. What’s new for the pathologist? Ann Pathol. 2003;23(6):492–5.PubMed
22.
Tuo YL, Li XM, Luo J. Long noncoding rna uca1 modulates breast cancer cell growth and apoptosis through decreasing tumor suppressive mir-143. Eur Rev Med Pharmacol Sci. 2015;19(18):3403–11.PubMed
23.
Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN. Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol. 2007;608:1–22.CrossRefPubMed
24.
Ponting CP, Oliver PL, Reik W. Evolution and functions of long noncoding rnas. Cell. 2009;136(4):629–41.CrossRefPubMed
25.
Guttman M, Donaghey J, Carey BW, Garber M, Grenier JK, Munson G, et al. LincRNAs act in the circuitry controlling pluripotency and differentiation. Nature. 2011;477(7364):295–300.CrossRefPubMedPubMedCentral
26.
Saison C, Helias V, Ballif BA, Peyrard T, Puy H, Miyazaki T, et al. Null alleles of ABCG2 encoding the breast cancer resistance protein define the new blood group system junior. Nat Genet. 2012;44(2):174–7.CrossRefPubMedPubMedCentral
27.
Chang JT, Mani SA. Sheep, wolf, or werewolf: cancer stem cells and the epithelial-to-mesenchymal transition. Cancer Lett. 2013;341(1):16–23.CrossRefPubMed
28.
29.
Pauli A, Valen E, Lin MF, Garber M, Vastenhouw NL, Levin JZ, et al. Systematic identification of long noncoding RNAs expressed during zebrafish embryogenesis. Genome Res. 2012;22(3):577–91.CrossRefPubMedPubMedCentral
30.
Sarrio D, Rodriguez-Pinilla SM, Hardisson D, Cano A, Moreno-Bueno G, Palacios J. Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. Cancer Res. 2008;68(4):989–97.CrossRefPubMed
31.
Hernandez-Aya LF, Gonzalez-Angulo AM. Adjuvant systemic therapies in breast cancer. Surg Clin N Am. 2013;93(2):473–91.CrossRefPubMed
32.
Vinod BS, Antony J, Nair HH, Puliyappadamba VT, Saikia M, Narayanan SS, et al. Mechanistic evaluation of the signaling events regulating curcumin-mediated chemosensitization of breast cancer cells to 5-fluorouracil. Cell Death Dis. 2013;4, e505.CrossRefPubMedPubMedCentral
33.
Kajiyama H, Shibata K, Terauchi M, Yamashita M, Ino K, Nawa A, et al. Chemoresistance to paclitaxel induces epithelial-mesenchymal transition and enhances metastatic potential for epithelial ovarian carcinoma cells. Int J Oncol. 2007;31(2):277–83.PubMed
34.
Du F, Wu X, Liu Y, Wang T, Qi X, Mao Y, et al. Acquisition of paclitaxel resistance via PI3K-dependent epithelial-mesenchymal transition in A2780 human ovarian cancer cells. Oncol Rep. 2013;30(3):1113–8.PubMed
35.
Wu Q, Wang R, Yang Q, Hou X, Chen S, Hou Y, et al. Chemoresistance to gemcitabine in hepatoma cells induces epithelial-mesenchymal transition and involves activation of PDGF-D pathway. Oncotarget. 2013;4(11):1999–2009.CrossRefPubMedPubMedCentral
Metadata
Title
Linc-ROR induces epithelial-mesenchymal transition and contributes to drug resistance and invasion of breast cancer cells
Authors
Yao-Min Chen
Yu Liu
Hai-Yan Wei
Ke-Zhen Lv
Peifen Fu
Publication date
01-08-2016
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 8/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-016-4909-1

Other articles of this Issue 8/2016

Tumor Biology 8/2016 Go to the issue

Original Article

Highly and moderately aggressive mouse ovarian cancer cell lines exhibit differential gene expression

Original Article

Potential risk of esophageal squamous cell carcinoma due to nucleotide excision repair XPA and XPC gene variants and their interaction among themselves and with environmental factors

Original Article

Hyperthermotherapy enhances antitumor effect of 5-aminolevulinic acid-mediated sonodynamic therapy with activation of caspase-dependent apoptotic pathway in human glioma

Original Article

The antitumor effect of TIG3 in liver cancer cells is involved in ERK1/2 inhibition

Original Article

miR-522 contributes to cell proliferation of hepatocellular carcinoma by targeting DKK1 and SFRP2

Original Article

Metformin and AICAR regulate NANOG expression via the JNK pathway in HepG2 cells independently of AMPK
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits